Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Ordinary Shares, nominal value Euro 0.12 per share
-
Shares outstanding
-
114,390,553
-
Total 13F shares
-
48,833,993
-
Share change
-
+15,486,597
-
Total reported value
-
$580,635,231
-
Price per share
-
$11.89
-
Number of holders
-
29
-
Value change
-
+$184,129,037
-
Number of buys
-
23
-
Number of sells
-
2
Institutional Holders of NewAmsterdam Pharma Co N.V. - Ordinary Shares, nominal value Euro 0.12 per share (NAMS) as of Q2 2023
As of 30 Jun 2023,
NewAmsterdam Pharma Co N.V. - Ordinary Shares, nominal value Euro 0.12 per share (NAMS) was held by
29 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
48,833,993 shares.
The largest 10 holders included
Frazier Life Sciences Management, L.P., Bain Capital Life Sciences Investors, LLC, RA CAPITAL MANAGEMENT, L.P., VIKING GLOBAL INVESTORS LP, Medicxi Ventures Management (Jersey) Ltd, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), BVF INC/IL, GMT CAPITAL CORP, ADAGE CAPITAL PARTNERS GP, L.L.C., and Eversept Partners, LP.
This page lists
29
institutional shareholders reporting positions in this security
for the Q2 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.